- Home
- DOUG vs ATOS Comparison
DOUG vs ATOS Comparison
Compare DOUG & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOUG
- ATOS
- Stock Information
- Founded
- DOUG 1911
- ATOS 2009
- Country
- DOUG United States
- ATOS United States
- Employees
- DOUG N/A
- ATOS N/A
- Industry
- DOUG Building operators
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- DOUG Real Estate
- ATOS Health Care
- Exchange
- DOUG Nasdaq
- ATOS Nasdaq
- Market Cap
- DOUG 146.0M
- ATOS 140.9M
- IPO Year
- DOUG N/A
- ATOS 2012
- Fundamental
- Price
- DOUG $1.88
- ATOS $1.04
- Analyst Decision
- DOUG
- ATOS Strong Buy
- Analyst Count
- DOUG 0
- ATOS 3
- Target Price
- DOUG N/A
- ATOS $7.00
- AVG Volume (30 Days)
- DOUG 1.1M
- ATOS 888.9K
- Earning Date
- DOUG 11-07-2024
- ATOS 11-12-2024
- Dividend Yield
- DOUG N/A
- ATOS N/A
- EPS Growth
- DOUG N/A
- ATOS N/A
- EPS
- DOUG N/A
- ATOS N/A
- Revenue
- DOUG $966,442,000.00
- ATOS N/A
- Revenue This Year
- DOUG $5.28
- ATOS N/A
- Revenue Next Year
- DOUG $16.40
- ATOS N/A
- P/E Ratio
- DOUG N/A
- ATOS N/A
- Revenue Growth
- DOUG 1.86
- ATOS N/A
- 52 Week Low
- DOUG $1.00
- ATOS $0.70
- 52 Week High
- DOUG $3.16
- ATOS $2.31
- Technical
- Relative Strength Index (RSI)
- DOUG 39.80
- ATOS 28.69
- Support Level
- DOUG $2.23
- ATOS $1.17
- Resistance Level
- DOUG $2.47
- ATOS $1.30
- Average True Range (ATR)
- DOUG 0.20
- ATOS 0.07
- MACD
- DOUG -0.08
- ATOS -0.01
- Stochastic Oscillator
- DOUG 7.34
- ATOS 12.50
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.